<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00370721</url>
  </required_header>
  <id_info>
    <org_study_id>8538</org_study_id>
    <nct_id>NCT00370721</nct_id>
  </id_info>
  <brief_title>Intravitreal Bevacizumab for Management of Active Progressive Proliferative Diabetic Retinopathy (PDR)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <brief_summary>
    <textblock>
      To evaluate the effect of intravitreal bevacizumab on the course of diabetic retinopathy in
      cases with the signs of active progressive PDR
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2006</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Regression of diabetic retinopathy</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>visual acuity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>neovascularization</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fibrous proliferation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>traction retinal detachment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vitreous hemorrhage</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pan retinal photocoagulation</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <arm_group_label>I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cases of active progressive PDR with history of scatter laser photocoagulation

        Exclusion Criteria:

          -  history of vitrectomy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hamid Ahmadieh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ophthalmic Research Center of Shaheed Beheshti Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hamid Ahmadieh, MD</last_name>
    <phone>+98 21 22585952</phone>
    <email>hahmadieh@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hamid Ahmadieh, MD</name>
      <address>
        <city>Tehran</city>
        <zip>16666</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hamid Ahmadieh, MD</last_name>
      <phone>+98 21 22585952</phone>
      <email>hahmadieh@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2006</study_first_submitted>
  <study_first_submitted_qc>August 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2006</study_first_posted>
  <last_update_submitted>June 25, 2008</last_update_submitted>
  <last_update_submitted_qc>June 25, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2008</last_update_posted>
  <keyword>Proliferative diabetic retinopathy(PDR)</keyword>
  <keyword>Pan retinal photocoagulation (PRP)</keyword>
  <keyword>Vitreous hemorrhage</keyword>
  <keyword>Traction retinal detachment</keyword>
  <keyword>Neovascularization on disc (NVD)</keyword>
  <keyword>Neovascularization elsewhere (NVE)</keyword>
  <keyword>Fibrous proliferation on disc (FPD)</keyword>
  <keyword>Fibrous proliferaiton elsewhere (FPE)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

